Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18125543 | 0.77 | CYP11B1 (0.42) | MEN1MAPTKMT2A | |
| SCHEMBL23641450 | 0.75 | APP (0.38) | HTR2CHTR2BHTR2ASLC6A4MAPT | |
| SCHEMBL30723523 | 0.75 | APP (0.38) | HTR2CHTR2BHTR2ASLC6A4MAPT | |
| SCHEMBL29778756 | 0.74 | SCN5A (0.34) | KCNH2 | |
| SCHEMBL23641255 | 0.74 | SCN5A (0.34) | KCNH2 | |
| SCHEMBL30892370 | 0.72 | ALOX5AP (0.40) | SMN1; SMN2 | |
| SCHEMBL24696642 | 0.72 | ALOX5AP (0.40) | SMN1; SMN2 | |
| SCHEMBL18114246 | 0.72 | MEN1 (0.34) | CA12CA1CA9CA2CA7 | |
| SCHEMBL12563479 | 0.72 | TAAR1 (0.42) | FGFR1 | |
| SCHEMBL27957723 | 0.72 | MAPT (0.50) | CA12CA1CA9CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20210198257-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2021-07-01 | — | — | US | disclosed |
| EP-3560924-B1 | IMIDAZOLONYL QUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-10745399-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | MERCK PATENT GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-3560924-A1 | IMIDAZOLONYL QUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | Merck Patent GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10457677-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | MERCK PATENT GMBH (DE) | 2019-10-29 | — | — | US | disclosed |
| US-20190211013-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2019-07-11 | — | — | US | disclosed |
| EP-3277681-B1 | IMIDAZOLONYLQUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2019-05-08 | — | — | EP | disclosed |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| WO-2016155884-A1 | IMIDAZOLONYL QUINOLINES AND USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | CA12 4884/4885CA1 4869/4885CA9 4859/4885 |
| US-20190211013-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | CA12 4884/4885CA1 4869/4885CA9 4859/4885 |
| US-10457677-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | ATM, CHEK2, CHEK1 | CA12 4872/4885CA1 4850/4885CA9 4388/4885 |
| US-20210198257-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | CA12 4884/4885CA1 4869/4885CA9 4859/4885 |
| US-10745399-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | ATM, CHEK2, CHEK1 | CA12 4860/4885CA1 4761/4885CA9 4391/4885 |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | CA12 4872/4885CA1 4850/4885CA9 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.